study,trt,class,mean,sd,se,n
ang 2013,cognitive behavioural therapy ,nonad,-3.19,,1.11,15
ang 2013,cognitive behavioral therapy and milnacipran ,snri,-2.65,,1.06,17
ang 2013,milnacipran ,snri,-2.93,,1.07,17
arnold 2002,placebo,placebo,1.1,2.5,,26
arnold 2002,fluoxetine ,ssri,-0.9,2.8,,25
arnold 2004,placebo,placebo,-0.52,,1.05,92
arnold 2004,duloxetine ,snri,-2.98,,1.04,91
arnold 2005,placebo,placebo,-2.6,,1,110
arnold 2005,duloxetine ,snri,-7.3,,1,111
arnold 2005,duloxetine ,snri,-6.7,,1,107
arnold 2010: 1,placebo,placebo,-1.81,,0.83,126
arnold 2010: 1,esreboxetine ,snri,-4.25,,0.83,126
arnold 2010: 2,placebo,placebo,0.5,,0.54,509
arnold 2010: 2,milnacipran ,snri,-1.54,,0.54,516
arnold 2010: 3,placebo,placebo,-1.3,,0.7,267
arnold 2010: 3,duloxetine ,snri,-5.1,,0.7,263
arnold 2012: 1,placebo,placebo,-3.91,,0.61,134
arnold 2012: 1,duloxetine ,snri,-5.47,,0.6,140
atkinson 1998,placebo,placebo,0.24,6.35,,40
atkinson 1998,nortriptyline ,tca,3.96,5.04,,38
branco 2010,placebo,placebo,0.23,,0.43,446
branco 2010,milnacipran ,snri,-1.23,,0.45,430
chappell 2008,placebo,placebo,-1.7,,0.37,143
chappell 2008,duloxetine ,snri,-2.04,,0.4,158
chappell 2009: 1,duloxetine ,snri,-0.11,,0.28,104
chappell 2009: 1,duloxetine ,snri,0.49,,0.21,203
chappell 2009: 2,placebo,placebo,1.03,9.34,,113
chappell 2009: 2,duloxetine ,snri,-1.06,8.84,,103
clauw 2008,placebo,placebo,-2.1,,0.6,401
clauw 2008,milnacipran ,snri,-2,,0.6,397
clauw 2008,milnacipran ,snri,-4,,0.6,393
enomoto 2018,pregabalin ,nonad,-2.5,,0.3,149
enomoto 2018,duloxetine ,snri,-2.3,,0.3,152
foster 2010: 1,placebo,placebo,-1.92,5.44,,29
foster 2010: 1,lidocaine ,nonad,-0.86,5.9,,30
foster 2010: 1,desipramine ,tca,-3.33,5.26,,27
foster 2010: 1,desipramine + lidocaine ,tca,-1.77,7.58,,32
frakes 2011,placebo,placebo,-4.15,,0.89,220
frakes 2011,duloxetine ,snri,-4.98,,0.88,216
gao 2010,placebo,placebo,-1.85,,0.23,109
gao 2010,duloxetine ,snri,-2.32,,0.24,106
goldstein 2005,placebo,placebo,-1.74,,0.48,79
goldstein 2005,duloxetine ,snri,-2.44,,0.48,82
goldstein 2005,duloxetine ,snri,-2.71,,0.49,78
goldstein 2005,duloxetine ,snri,-3.11,,0.5,74
iwaki 2020,placebo,placebo,-0.43,,1.38,23
iwaki 2020,duloxetine ,snri,-1.22,,1.22,23
miki 2016,placebo,placebo,-2.54,0.47,,202
miki 2016,mirtazapine ,nassa,-2.77,0.46,,204
murakami 2015,placebo,placebo,2,,2.52,195
murakami 2015,duloxetine ,snri,-5.91,,2.51,191
norregaard 1995,placebo,placebo,0.9,7.9,,21
norregaard 1995,citalopram ,ssri,1,6.1,,21
raskin 2005,placebo,placebo,-0.55,,0.25,101
raskin 2005,duloxetine ,snri,-1.17,,0.25,103
raskin 2005,duloxetine ,snri,-0.65,,0.25,100
rowbotham 2012,placebo,placebo,-2.8,,1.2,49
rowbotham 2012,duloxetine ,snri,-2.3,,1.2,55
rowbotham 2012,abt-894 ,nonad,-4.8,,1.1,60
rowbotham 2012,abt-894 ,nonad,-0.9,,1.2,53
rowbotham 2012,abt-894 ,nonad,-3.2,,1.2,53
russell 2008,placebo,placebo,-1.75,,1,144
russell 2008,duloxetine ,snri,-2.56,,1.28,79
russell 2008,duloxetine ,snri,-3.68,,0.97,150
russell 2008,duloxetine ,snri,-4.41,,0.97,147
shinichi 2016,placebo,placebo,-1.83,,0.11,200
shinichi 2016,duloxetine ,snri,-2.15,,0.11,209
skljarevski 2009,placebo,placebo,-1.02,,0.49,114
skljarevski 2009,duloxetine ,snri,-1.24,,0.68,57
skljarevski 2009,duloxetine ,snri,-1.54,,0.5,109
skljarevski 2009,duloxetine ,snri,0.37,,0.5,108
skljarevski 2010: 1,placebo,placebo,0.49,10.45,,106
skljarevski 2010: 1,duloxetine ,snri,-2.05,9.9,,102
skljarevski 2010: 2,placebo,placebo,-2.77,,0.95,180
skljarevski 2010: 2,duloxetine ,snri,-6.77,,0.93,181
talley 2008,placebo,placebo,1.9,7.2,,16
talley 2008,imipramine ,tca,-4.8,4.5,,18
talley 2008,citalopram ,ssri,0,4.1,,17
tesfaye 2013,pregabalin ,nonad,-0.64,2.9,,399
tesfaye 2013,duloxetine ,snri,-1.06,2.9,,399
uchio 2018,placebo,placebo,-1.48,,0.99,176
uchio 2018,duloxetine ,snri,-3.02,,0.99,177
vollmer 2014,placebo,placebo,-3,,0.6,121
vollmer 2014,duloxetine ,snri,-2.4,,0.6,118
wang 2017,placebo,placebo,-1.04,,0.13,177
wang 2017,duloxetine ,snri,-1.43,,0.13,172
wernicke 2006,placebo,placebo,-0.64,,0.26,95
wernicke 2006,duloxetine ,snri,-0.65,,0.26,97
wernicke 2006,duloxetine ,snri,0.19,,0.26,101
yasuda 2011,placebo,placebo,-1.91,,0.24,167
yasuda 2011,duloxetine ,snri,-2.18,,0.29,85
yasuda 2011,duloxetine ,snri,-2.39,,0.29,86